Short answer
Trevi Therapeutics, Inc. (TRVI) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results announced for quarter ended June 30, 2026.
Trevi Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results announced for quarter ended June 30, 2026
- Full results and management commentary furnished in Exhibit 99.1
- Investor focus: quarterly cash position, operating expenses, clinical progress, and runway in the accompanying release
Item EX-99.1 · Exhibit EX-99.1
- Phase 3 OCEAN-1 initiated for IPF-related chronic cough; topline data expected first half 2028
- Phase 3 OCEAN-2 expected to start third quarter 2026; topline results targeted second half 2027
- Phase 2b LAKE initiated for refractory chronic cough; sample-size re-estimation expected fourth quarter 2026
- Cash, equivalents and marketable securities $318.9M after $162.3M April offering; runway projected into 2030
- Second-quarter net loss $17.8M versus $12.3M; R&D increased to $15.2M from $9.4M as pivotal trials advanced
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Trevi Therapeutics, Inc. 8-K filings
Get the next TRVI 8-K as it lands
Follow TRVI for push alerts, or ask the research agent what this filing means.